Payment overview · 2025
General Payments
$2,232.02
46 reported records · 17 companies
Healthcare provider profile · identity verified
Ashraf N. Nashed, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · THOUSAND OAKS, CA · NPI 1144290081
Verified facts
What the public records show
CMS Open Payments records show Ashraf N. Nashed, MD received $2,232.02 in general payments during 2025 across 46 reported records.
Philips North America LLC accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Verquvo.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 415 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 416 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 415 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $768.75 | 34.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $261.24 | 11.7% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $235.95 | 10.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.96 | 7.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $156.21 | 7.0% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $116.41 | 5.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.07 | 4.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.53 | 3.7% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $62.99 | 2.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $62.87 | 2.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.05 | 2.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.37 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $39.11 | 1.8% | 2 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $28.75 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.59 | 1.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.30 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.87 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,582.03 | 44 |
| Travel and Lodging | $649.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $465.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $261.24 | 4 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $224.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $158.96 | 7 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $140.75 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $120.89 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $95.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.07 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.53 | 4 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $79.16 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $62.99 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $62.87 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $39.02 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.59 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $25.49 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 416 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 114 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 415 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 271 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
42 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
415 | 57 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
416 | 61 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
415 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
271 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
87 | 12 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1213 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 607 | 91 |
| Furosemide | Furosemide | 576 | 102 |
| Carvedilol | Carvedilol | 504 | 84 |
| Clopidogrel | Clopidogrel Bisulfate | 493 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 80 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 429 | 80 |
| Eliquis | Apixaban | 416 | 61 |
| Jardiance | Empagliflozin | 415 | 57 |
| Ezetimibe | Ezetimibe | 412 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 411 | 78 |
| Potassium Chloride | Potassium Chloride | 402 | 80 |
| Losartan Potassium | Losartan Potassium | 400 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 397 | 64 |
| Ozempic | Semaglutide | 376 | 58 |
| Metformin Hcl | Metformin Hcl | 354 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 63 |
| Gabapentin | Gabapentin | 305 | 54 |
| Omeprazole | Omeprazole | 295 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 288 | 54 |
| Mounjaro | Tirzepatide | 271 | 49 |
| Xarelto | Rivaroxaban | 266 | 30 |
| Nateglinide | Nateglinide | 250 | 37 |
| Lisinopril | Lisinopril | 237 | 40 |
| Nifedipine Er | Nifedipine | 225 | 36 |
| Atenolol | Atenolol | 199 | 30 |
| Sertraline Hcl | Sertraline Hcl | 199 | 32 |
| Linzess | Linaclotide | 196 | 30 |
| Alprazolam | Alprazolam | 189 | 34 |
| Methenamine Hippurate | Methenamine Hippurate | 189 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 36 |
| Finasteride | Finasteride | 184 | 30 |
| Allopurinol | Allopurinol | 176 | 33 |
| Tramadol Hcl | Tramadol Hcl | 172 | 45 |
| Trazodone Hcl | Trazodone Hcl | 168 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 167 | 35 |
| Januvia | Sitagliptin Phosphate | 162 | 19 |
| Clonidine Hcl | Clonidine Hcl | 156 | 38 |
| Vascepa | Icosapent Ethyl | 152 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 35 |
| Azithromycin | Azithromycin | 141 | 84 |
| Warfarin Sodium | Warfarin Sodium | 137 | 11 |
| Montelukast Sodium | Montelukast Sodium | 133 | 22 |
| Clonidine | Clonidine | 132 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 132 | 15 |
| Famotidine | Famotidine | 129 | 18 |
| Celecoxib | Celecoxib | 124 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 123 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 122 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 25 |
| Entresto | Sacubitril/Valsartan | 114 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 30 |
| Nitroglycerin | Nitroglycerin | 110 | 33 |
| Digoxin | Digoxin | 108 | 21 |
| Multaq | Dronedarone Hcl | 97 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 96 | 17 |
| Repatha Sureclick | Evolocumab | 92 | 15 |
| Trulicity | Dulaglutide | 87 | 12 |
| Benazepril Hcl | Benazepril Hcl | 84 | 15 |
| Ranolazine Er | Ranolazine | 79 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 76 | 15 |
| Mirtazapine | Mirtazapine | 74 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 14 |
| Baclofen | Baclofen | 71 | 24 |
| Brilinta | Ticagrelor | 71 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 39 |
| Pregabalin | Pregabalin | 69 | 12 |
| Lidocaine | Lidocaine | 66 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 60 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | suppressed |
| Levetiracetam | Levetiracetam | 56 | suppressed |
| Spironolactone | Spironolactone | 56 | suppressed |
| Metolazone | Metolazone | 55 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 14 |
| Sucralfate | Sucralfate | 52 | suppressed |
| Bupropion Xl | Bupropion Hcl | 49 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Lorazepam | Lorazepam | 48 | 14 |
| Midodrine Hcl | Midodrine Hcl | 48 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | suppressed |
| Prolia | Denosumab | 42 | 29 |
| Valsartan | Valsartan | 42 | suppressed |
| Colchicine | Colchicine | 41 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Creon | Lipase/Protease/Amylase | 40 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Temazepam | Temazepam | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 13 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Lactulose | Lactulose | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Prednisone | Prednisone | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 18 |
| Liothyronine Sodium | Liothyronine Sodium | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 21 |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Anastrozole | Anastrozole | 20 | suppressed |
| Forteo | Teriparatide | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Jublia | Efinaconazole | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Verquvo | Vericiguat | 18 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Ztlido | Lidocaine | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mercaptopurine | Mercaptopurine | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,232.02 · 46 records | Philips North America LLC | CAMZYOS, Coronary Other, Coronary Undivided, ELIQUIS, ENTRESTO, FARXIGA, IGT Devices Undivided, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, NEXLETOL, Ohtuvayre, Optimizer, REPATHA, SHINGRIX, VERQUVO, VOWST, WATCHMAN Access System, WATCHMAN FLX, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error